AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Nasopharyngeal Cancer Market Outlook, 2019-2024: Drivers, Restraints, Challenges and Opportunities - ResearchAndMarkets.com

December 2, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Dec 2, 2019--

The “Nasopharyngeal Cancer Market - Growth, Trends, and Forecast (2019 - 2024)” report has been added to ResearchAndMarkets.com’s offering.

Global Nasopharyngeal Cancer market is expected to witness a steady CAGR of 2.2% during the forecast period.

Certain factors that are driving the market growth include a moderate rise in the burden of the disease and growing awareness towards diagnosis and treatment.

There is a growing awareness of the diagnosis and treatment of nasopharyngeal cancer (NPC). Traditionally the public perception regarding nasopharyngeal cancer was very weak due to lack of government initiatives and low incidence rate of the disease. But, the rise in the number of NPC patients in North America region has changed this scenario.

In the United States, nasopharyngeal carcinoma (NPC) is a rare malignancy of the upper digestive tract and has an incidence of less than 1 per 100,000. However, this disease has a well-documented regional and ethnic distribution such that individuals of Southern Chinese and Southeast Asian descent are up to 20-40 times more likely to develop NPC than individuals of European ethnicity.

To increase community awareness for ethnicities, which are predisposed to nasopharyngeal cancer, various primary healthcare centers have started awareness campaigns to increase the awareness of NPC. Consequently, greater adoption of NPC diagnosis and treatment is being witnessed, which is driving the growth of the global nasopharyngeal cancer market.

Key Market Trends

Radiation Therapy is Expected to Hold Significant Market Share in the Treatment Type Segment

Radiation therapy forms the primary modality of treatment in nasopharyngeal cancer. It is closely followed by chemotherapy in terms of both market share and use-case in patients. Newer and advanced modalities of nasopharyngeal cancer treatment include a combination of both radiotherapy and chemotherapy techniques. These treatment modalities are still in early clinical phases and will make a commercial appearance late during the end of the forecast period or maybe even after that.

Asia-Pacific Dominates the Market and Expected to do Same in the Forecasted Period

In Asia pacific, nasopharyngeal cancer is one of the most common cancers in the head and neck areas. Men are two to three times more likely to develop it than women. The peak age of incidence is between 50 and 60 years. Nasopharyngeal cancer is generally more common in Southeast Asia. The five countries with the highest incidence of nasopharyngeal cancer in the world were China, Indonesia, Vietnam, India and Malaysia, respectively. The standard incidence of nasopharyngeal cancer in the world was 1.2 per 100,000 (in men 1.7 per 100,000; in women, 0.7 per 100,000).

Competitive Landscape

The global Nasopharyngeal Cancer market is highly competitive and consists of a few major players. Companies like Biocon, Bristol Myers Squibb, Cyclacel Pharmaceuticals, F. Hoffman La-Roche, Merck & Co., Novartis, Pfizer, among others, hold the substantial market share in the Nasopharyngeal Cancer market.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Burden of the Cancer Disease

4.2.2 Growing Awareness Towards Diagnosis and Treatment

4.3 Market Restraints

4.3.1 High Cost of the Treatment

4.3.2 Side Effects Associated with the Disease

4.4 Porter’s Five Force Analysis

5 MARKET SEGMENTATION

5.1 Treatment Type

5.1.1 Chemotherapy

5.1.2 Radiation Therapy

5.1.3 Others

5.2 Geography

5.2.1 North America

5.2.1.1 US

5.2.1.2 Canada

5.2.1.3 Mexico

5.2.2 Europe

5.2.2.1 Germany

5.2.2.2 UK

5.2.2.3 France

5.2.2.4 Italy

5.2.2.5 Spain

5.2.2.6 Rest of Europe

5.2.3 Asia Pacific

5.2.3.1 China

5.2.3.2 Japan

5.2.3.3 India

5.2.3.4 Australia

5.2.3.5 South Korea

5.2.3.6 Rest of Asia-Pacific

5.2.4 Middle East and Africa

5.2.4.1 GCC

5.2.4.2 South Africa

5.2.4.3 Rest of Middle East and Africa

5.2.5 South America

5.2.5.1 Brazil

5.2.5.2 Argentina

5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Biocon Limited

6.1.2 Bristol Myers Squibb

6.1.3 Cyclacel Pharmaceuticals

6.1.4 F. Hoffman La-Roche

6.1.5 Merck & Co. Inc.

6.1.6 Novartis AG

6.1.7 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/i7wfcg

View source version on businesswire.com:https://www.businesswire.com/news/home/20191202005883/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 12/02/2019 02:34 PM/DISC: 12/02/2019 02:34 PM

http://www.businesswire.com/news/home/20191202005883/en